Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Andre

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Personalized Medicine|May 23, 2018
Tumor genotyping for breast cancer: at the front doorMonica Arnedos, Fabrice Andre
European Journal of Cancer (Oxford, England : 1990)|August 30, 2023
A forgotten dimension of big data in drug repositioningElie Rassy, Fabrice Andre
The Lancet. Oncology|December 17, 2009
First-generation genomic tests for breast cancer treatmentFabrice Andre, Suzette Delaloge
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Neoadjuvant chemotherapy for breast cancers: current recommendations and future directionsFabrice Andre, Suzette Delaloge
Pharmaceutical Research|August 15, 2006
Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapyFabrice Andre, Lajos Pusztai
Nature Clinical Practice. Oncology|November 3, 2006
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapyFabrice Andre, Lajos Pusztai
BMC Medicine|October 7, 2014
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trialsPernelle Lavaud, Fabrice Andre
The Oncologist|September 4, 2023
Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?Elie Rassy, Fabrice Andre
The Lancet. Oncology|May 16, 2015
Bevacizumab: the phoenix of breast oncology?Fabrice Andre, Elise Deluche, Herve Bonnefoi
Current Opinion in Oncology|September 16, 2010
Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patientsFabrice Andre, Narjiss Berrada, Christine Desmedt
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Personalized Medicine|May 23, 2018
Tumor genotyping for breast cancer: at the front doorMonica Arnedos, Fabrice Andre
European Journal of Cancer (Oxford, England : 1990)|August 30, 2023
A forgotten dimension of big data in drug repositioningElie Rassy, Fabrice Andre
The Lancet. Oncology|December 17, 2009
First-generation genomic tests for breast cancer treatmentFabrice Andre, Suzette Delaloge
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Neoadjuvant chemotherapy for breast cancers: current recommendations and future directionsFabrice Andre, Suzette Delaloge
Pharmaceutical Research|August 15, 2006
Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapyFabrice Andre, Lajos Pusztai
Nature Clinical Practice. Oncology|November 3, 2006
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapyFabrice Andre, Lajos Pusztai
BMC Medicine|October 7, 2014
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trialsPernelle Lavaud, Fabrice Andre
The Oncologist|September 4, 2023
Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?Elie Rassy, Fabrice Andre
The Lancet. Oncology|May 16, 2015
Bevacizumab: the phoenix of breast oncology?Fabrice Andre, Elise Deluche, Herve Bonnefoi
Current Opinion in Oncology|September 16, 2010
Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patientsFabrice Andre, Narjiss Berrada, Christine Desmedt
Pageof 15